About all

What is tizanidine 4mg used for: Tizanidine (Oral Route) Description and Brand Names

Tizanidine Uses, Dosage, Side Effects

Generic name: tizanidine [ tye-ZAN-i-deen ]
Brand name: Zanaflex
Drug class: Skeletal muscle relaxants

Medically reviewed by Sanjai Sinha, MD. Last updated on Jan 10, 2022.

What is tizanidine?

Tizanidine is a short-acting muscle relaxer. It works by blocking nerve impulses (pain sensations) that are sent to your brain.

Tizanidine is used to treat spasticity by temporarily relaxing muscle tone.

Tizanidine may also be used for purposes not listed in this medication guide.

Warnings

Tizanidine is a short-acting medication that should be taken only for daily activities that require relief from muscle spasticity.

You should not take tizanidine if you are also taking fluvoxamine (Luvox) or ciprofloxacin (Cipro).

Do not use tizanidine at a time when you need muscle tone for safe balance and movement during certain activities. In some situations, it may endanger your physical safety to be in a state of reduced muscle tone.

Switching between tablets and capsules, or changing the way you take it with regard to eating, can cause an increase in side effects or a decrease in therapeutic effect. Follow your doctor’s instructions carefully. After making any changes in how you take tizanidine, contact your doctor if you notice any change in how well the medicine works or if it causes increased side effects.

The recommended starting dose of tizanidine is 2 mg every 6 to 8 hours, up to a maximum of 3 doses in 24 hours. Do not take more than 36 mg of tizanidine in a 24-hour period. Too much of this medicine can damage your liver. Cold or allergy medicine, narcotic pain medicine, sleeping pills, other muscle relaxers, and medicine for seizures, depression or anxiety can add to sleepiness caused by tizanidine.

Avoid drinking alcohol. It can increase some of the side effects of this medicine.

Before taking this medicine

You should not use tizanidine if you are allergic to it, or if:

To make sure tizanidine is safe for you, tell your doctor if you have ever had:

  • liver disease;

  • kidney disease; or

  • low blood pressure.

It is not known whether tizanidine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.

How should I take tizanidine?

Take tizanidine exactly as it was prescribed for you. Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not use this medicine in larger or smaller amounts or for longer than recommended.

Tizanidine is usually taken up to 3 times in one day, starting at 2mg per dose. Allow 6 to 8 hours to pass between doses. Do not take more than 36 mg in a 24-hour period. Too much of this medicine can damage your liver.

You may take tizanidine with or without food, but take it the same way each time. Switching between taking with food and taking it without food can make the medicine less effective or cause increased side effects.

Switching between tablets and capsules may cause changes in side effects or how well the medicine works.

If you make any changes in how you take tizanidine, tell your doctor if you notice any change in side effects or in how well the medicine works.

Tizanidine is a short-acting medication, and its effects will be most noticeable between 1 and 3 hours after you take it. You should take this medicine only for daily activities that require relief from muscle spasms.

You will need frequent blood tests to check your liver function.

If you stop using this medicine suddenly after long-term use, you may have withdrawal symptoms such as dizziness, fast heartbeats, tremors, and anxiety. Ask your doctor how to safely stop using this medicine.

Store at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include weakness, drowsiness, confusion, slow heart rate, shallow breathing, feeling light-headed, or fainting.

What to avoid

Do not use tizanidine at a time when you need muscle tone for safe balance and movement during certain activities. In some situations, it may be dangerous for you to have reduced muscle tone.

Drinking alcohol with this medicine can cause side effects.

Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired. Avoid getting up too fast from a sitting or lying position, or you may feel dizzy.

Tizanidine side effects

Get emergency medical help if you have signs of an allergic reaction to tizanidine: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • a light-headed feeling, like you might pass out;

  • weak or shallow breathing;

  • confusion, hallucinations; or

  • pain or burning when you urinate.

Common tizanidine side effects may include:

  • drowsiness, dizziness, weakness;

  • feeling nervous;

  • blurred vision;

  • flu-like symptoms;

  • dry mouth, trouble speaking;

  • abnormal liver function tests;

  • runny nose, sore throat;

  • urination problems, painful urination;

  • vomiting, constipation; or

  • uncontrolled muscle movements.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect tizanidine?

Taking tizanidine with other drugs that make you sleepy or slow your breathing can cause dangerous side effects or death. Ask your doctor before using opioid medication, a sleeping pill, a muscle relaxer, or medicine for anxiety or seizures.

Tell your doctor about all your other medicines, especially:

  • acyclovir;

  • ticlopidine;

  • zileuton;

  • birth control pills;

  • an antibiotic – ciprofloxacin, levofloxacin, moxifloxacin, or ofloxacin;

  • blood pressure medicine – clonidine, guanfacine, methyldopa;

  • heart rhythm medicine – amiodarone, mexiletine, propafenone, verapamil; or

  • stomach acid medicine – cimetidine, famotidine.

This list is not complete. Other drugs may interact with tizanidine, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Popular FAQ

The maximum effect of tizanidine occurs about 1 hour to 2 hours after taking a dose. It wears off in about 3 to 6 hours after taking it. Tizanidine is typically given no more than 3 times a day.

Tizanidine is not listed as a controlled substance by the U.S. Drug Enforcement Administration (DEA). Abuse potential has not been evaluated in human studies.

Tizanidine can cause sleepiness, but it has not been approved by the U.S. Food and Drug Administration (FDA) to treat sleep disorders. Tizanidine is a skeletal muscle relaxant. It is approved by the FDA to help relieve muscle spasms.

Tizanidine is known to cause low blood pressure. In some cases, it may cause low blood pressure that is so low that you could faint or pass out. The chances of fainting can be lowered if your doctor raises the dose of tizanidine very slowly. You may also have to be careful when you move from a sitting position to a standing position. In clinical trials, the most common side effects of tizanidine were dry mouth, sleepiness, dizziness and asthenia (defined as weakness, fatigue and/or tiredness).

Tizanidine normally starts working 1 to 2 hours after taking it. It wears off about 3 hours to 6 hours after taking it. Tizanidine can be taken up to 3 times a day to help relieve muscle spasms.

Tizanidine may be addictive, but it has not been evaluated in human studies. Withdrawal symptoms have been reported after abruptly stopping tizanidine, but abuse of other medications concomitantly was suspected in these cases. Dosing should be tapered off to avoid possible withdrawal symptoms.

Tizanidine is not known to cause weight gain. In clinical trials, the most common side effects of tizanidine were dry mouth, sleepiness, dizziness and asthenia (defined as weakness, fatigue and/or tiredness).

More about tizanidine

  • Check interactions
  • Compare alternatives
  • Pricing & coupons
  • Reviews (371)
  • Drug images
  • Side effects
  • Dosage information
  • Patient tips
  • During pregnancy
  • Support group
  • Drug class: skeletal muscle relaxants
  • En español

Patient resources

Other brands

Zanaflex

Professional resources

  • Prescribing Information

Related treatment guides

  • Muscle Spasm
  • Cluster Headaches

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use tizanidine only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2023 Cerner Multum, Inc. Version: 4.01.

Tizanidine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Uses

This medication is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury). It works by helping to relax the muscles.

How to use Tizanidine HCL

Take this medication by mouth as directed by your doctor, usually every 6 to 8 hours.

The dosage is based on your medical condition, response to treatment, and other medications you may be taking. Be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products). To reduce your risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor’s instructions carefully. Do not take more than 36 milligrams a day or more than 3 doses in a 24-hour period.

Your body will absorb this medication differently depending on whether you take it as a tablet or capsule, whether you take it with food or on an empty stomach, or if you sprinkle the contents of the capsule on food. Be sure to discuss with your doctor how to take this medication to determine the best way to take your dose, especially when changes to your dose are being considered or if your doctor prescribes a different form of tizanidine (such as tablet or capsule).

If you suddenly stop using this medication, you may have withdrawal symptoms (such as anxiety, tremor, increased blood pressure/heart rate/muscle tenseness). To help prevent withdrawal, your doctor may lower your dose slowly. Withdrawal is more likely if you have used tizanidine for a long time or in high doses. Tell your doctor or pharmacist right away if you have withdrawal.

Tell your doctor if your condition does not improve or if it worsens.

Side Effects

Dry mouth, drowsiness, dizziness, lightheadedness, constipation, weakness, and tiredness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

To relieve dry mouth, suck (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water, or use a saliva substitute.

To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.

Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: fainting, mental/mood changes (such as hallucinations), slow/irregular heartbeat, vision changes (such as blurred vision).

Tizanidine has rarely caused very serious (rarely fatal) liver disease. Tell your doctor right away if you develop symptoms of liver disease, including: nausea/vomiting that doesn’t stop, severe stomach/abdominal pain, dark urine, yellowing eyes/skin.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US – Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before taking tizanidine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: low blood pressure, kidney disease, liver disease.

This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Older adults may be more sensitive to the side effects of this drug, especially dizziness and drowsiness. These effects can increase the risk of falling.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.

Some products that may interact with this drug include: certain drugs to treat high blood pressure (alpha agonists such as clonidine, methyldopa).

Other medications can affect the removal of tizanidine from your body, which may affect how tizanidine works. Examples include birth control pills, ciprofloxacin, fluvoxamine, viloxazine, among others.

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, marijuana (cannabis), antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and opioid pain relievers (such as codeine).

Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.

Does Tizanidine HCL interact with other drugs you are taking?

Enter your medication into the WebMD interaction checker

Overdose

If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe dizziness/drowsiness, confusion, slow/shallow breathing, fainting.

Do not share this medication with others.

Lab and/or medical tests (such as blood pressure, liver function) should be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.

If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Images

tizanidine 2 mg tablet

Color: whiteShape: roundImprint: U 168

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg tablet

Color: whiteShape: roundImprint: 1 1 04

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg tablet

Color: whiteShape: roundImprint: APO TI-4

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg tablet

Color: whiteShape: ovalImprint: R180

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg tablet

Color: whiteShape: ovalImprint: R179

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg tablet

Color: whiteShape: roundImprint: U 169

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg tablet

Color: whiteShape: roundImprint: APO TI-2

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg tablet

Color: whiteShape: roundImprint: 503

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg tablet

Color: whiteShape: roundImprint: E 44

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg tablet

Color: whiteShape: roundImprint: 1105

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg capsule

Color: light blueShape: oblongImprint: 1111

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg capsule

Color: white,blueShape: oblongImprint: 4 MG

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg capsule

Color: light blueShape: oblongImprint: 2 MG

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 6 mg capsule

Color: blueShape: oblongImprint: 6 MG

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg tablet

Color: whiteShape: roundImprint: 502

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg capsule

Color: light blueShape: oblongImprint: 2MG Tiza

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg capsule

Color: blueShape: oblongImprint: APO T2

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 6 mg capsule

Color: light blue,whiteShape: oblongImprint: C 672

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg capsule

Color: light blueShape: oblongImprint: C 671

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg capsule

Color: white,blueShape: oblongImprint: C 670

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 6 mg capsule

Color: blueShape: oblongImprint: APO T6

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg capsule

Color: white,blue-greenShape: oblongImprint: APO T4

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 6 mg capsule

Color: blueShape: oblongImprint: ING 226 ING 226

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg capsule

Color: light blue,whiteShape: oblongImprint: ING 225 ING 225

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg tablet

Color: whiteShape: roundImprint: M 724

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg capsule

Color: light blueShape: oblongImprint: ING 224 ING 224

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 6 mg capsule

Color: violetShape: oblongImprint: 1113

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg capsule

Color: white,violetShape: oblongImprint: 1112

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 4 mg capsule

Color: white,blueShape: oblongImprint: 4MG Tiza

This medicine is a white, round, scored, tablet imprinted with “U 168”.

tizanidine 2 mg tablet

Color: whiteShape: roundImprint: M 722

This medicine is a white, round, scored, tablet imprinted with “U 168”.

Next

Save up to 80% on your prescriptions.

Available coupons

Save up to 80% on your prescription with WebMDRx

Drug Survey

Are you currently using Tizanidine HCL?

This survey is being conducted by the WebMD marketing sciences department.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

The use of tizanidine (Sirdalud) in the treatment of pain and spasm | Danilov A.B.

The drug tizanidin (Sirdalud) belongs to the centrally acting muscle relaxants (α2-adrenergic agonists) and implements its effect at the spinal and supraspinal levels [4]. By stimulating presynaptic α2 receptors, it inhibits the release of excitatory amino acids that stimulate NMDA receptors. This leads to the suppression of the transmission of excitation through the polysynaptic reflexes of the spinal cord. The drug mainly inhibits the polysynaptic reflexes of the spinal cord responsible for muscle hypertonicity, which causes a decrease in the increased tone of the flexor and extensor muscles and a decrease in painful muscle spasms. In addition to muscle relaxant properties, tizanidine also has a central, moderately pronounced analgesic effect (by reducing the release of excitatory neurotransmitters in the brain at the level of the locus coeruleus). In animal studies, it has been shown that tizanidine (Sirdalud) can realize its effect through a decrease in central sensitization [11]. These properties of tizanidine allow it to be used both as a means to reduce muscle spasm, and for the treatment of a number of pain syndromes (associated with muscle spasm).

Tizanidin (Sirdalud)
for pain syndromes
Monotherapy with tizanidine (Sirdalud) for pain syndromes. Muscular tonic and myofascial pain syndromes are very often the main reason for patients to seek medical attention. In the treatment of muscular-tonic pain, the central place belongs to local influences aimed at relaxing the muscle (massage, applications of warming ointments, gels, wet compresses, etc.), and in the case of myofascial pain syndrome, on the destruction of trigger points using post-isometric relaxation, the introduction of dry needles or anesthetic into the trigger zone. The terms of therapy are significantly reduced with effective anesthesia of the patient. A common method of pain relief for myofascial pain is also the use of non-steroidal anti-inflammatory drugs (NSAIDs).
Muscle relaxants can be of great help in the treatment of muscular-tonic and myofascial pain syndromes by reducing the intensity of pain, reducing painful muscle tension, and improving motor activity. The use of muscle relaxants is justified by the recognition of the important role of muscle spasm in the pathogenesis of pain in the lower back. Pain of various origins (due to damage to the intervertebral discs, facet joints of the spine, the muscles themselves and other causes) increases the activity of the motor neurons of the spinal cord, which leads to muscle spasm, which in turn plays a significant role in maintaining the pain itself. Pathologically increased muscle tone has various mechanisms for increasing pain: direct irritation of muscle pain receptors, deterioration of blood supply to the muscles, which leads to the formation of a vicious circle leading to increased muscle spasm and accompanying pain. Muscle relaxants break the vicious circle of “pain – muscle spasm – pain” and, as a result, can accelerate the recovery period [6]. In European guidelines for the treatment of acute pain in the lower back, tizanidine, dantrolene, diazepam, baclofen are noted as effective muscle relaxants [19]. In our country, of these drugs, tizanidine (Sirdalud) is most commonly used [6].
The effective daily dose range of tizanidine (Sirdalud) for pain syndromes is 2–12 mg (the optimal dose is 6–8 mg/day). For mild pain syndromes, the appointment of tizanidine (Sirdalud) can be limited to taking the drug at night at a dose of 2-4 mg until the pain stops (usually 5-7 days). With a moderately severe pain syndrome, it is also better to prescribe the first dose at night at a dose of 2–4 mg (the patient will “oversleep” the side effects), then gradually increase the dose to 6–8 mg / day. In severe cases, an additional 2–4 mg of tizanidine (Sirdalud) at night can be added. A positive effect, as a rule, is already noted on the 3rd day of taking the drug. In chronic pain syndromes, a course of therapy is usually carried out lasting 2-4 weeks, adjusting the duration of treatment and the dose of the drug depending on the efficacy / tolerability.
It should be noted that for mild to moderate pain associated with muscle spasm (eg, acute pain in the neck or lower back), it may be sufficient to prescribe tizanidine (Sirdalud) as monotherapy.
The effectiveness of tizanidine monotherapy (Sirdalud) has been confirmed in many studies, incl. and in a multicenter study that included 2251 patients with acute pain caused by muscle spasm in the lower back, neck, or shoulder. 89% of patients rated the treatment outcome as “good” or “very good”. The study also noted a very good tolerability of the drug (90% of patients reported tolerability as “good” or “very good”). These results allowed the authors to recommend tizanidine as the drug of choice among muscle relaxants for the treatment of pain associated with muscle spasm [13].
Combination of tizanidine (Sirdalud) with NSAIDs. With more severe pain, or when it is based on inflammatory changes, it is advisable to use tizanidine and NSAIDs together. Studies show that the use of tizanidine potentiates the effect of NSAIDs [9,16]. In addition, taking tizanidine (Sirdalud) has a gastroprotective effect, which is associated with its adrenergic activity and antispasmodic effect. Tizanidin (Sirdalud) reduces basal and induced acid secretion in the stomach, eliminates the imbalance of glycoproteins in the gastric mucosa and gastric secretions [11,16].
In experimental studies, the use of tizanidine demonstrated a significant decrease in the ulcerogenic effect of acetylsalicylic acid, indomethacin, meloxicam, nimesulide and naproxen. The gastroprotective activity of tizanidine has also been proven in clinical studies. In patients receiving the combination of ibuprofen and tizanidine, the frequency of gastrointestinal side effects, including bleeding, was significantly (p = 0.002) lower than in patients receiving the combination of ibuprofen and placebo [9]. Similar results were obtained when comparing the combination of diclofenac and tizanidine with the combination of diclofenac and placebo in a multicenter (12 centers), prospective, double-blind, placebo-controlled, randomized clinical trial conducted in 6 countries of the Asia-Pacific region and including 405 participants [16]. Gastropathy was reported in 12% of patients treated with a combination of diclofenac and tizanidine versus 32% of patients treated with diclofenac in combination with placebo (p<0.001). The frequency of positive fecal occult blood test results was 5% in the main group compared to 11% in the control group.
The gastroprotective effect of Sirdalud is especially important for the management of patients with chronic pain syndromes who take NSAIDs for a long period of time (for rheumatological diseases), which often leads to the development of erosive gastritis and gastric and duodenal ulcers [1].
Combination of tizanidine (Sirdalud) with antidepressants and anticonvulsants. The management of chronic pain is more complex than the management of acute pain and requires an integrated approach. The use of muscle relaxants here is only a component of treatment and should be justified by the presence of a therapeutic target – muscle spasm. In this regard, the patient’s expectations regarding the effect of a muscle relaxant should be correctly formed: the use of tizanidine (Sirdalud) can reduce pain, facilitate the patient’s movements, but will not stop the pain completely, because. in chronic pain, the muscle component is not the leading one.
In the treatment of chronic pain syndromes, anticonvulsants, antidepressants are used, so it is important to consider how tizanidine (Sirdalud) interacts with these drugs. There are works that show that tizanidine (Sirdalud) potentiates the action of tricyclic antidepressants (amitriptyline) [10]. At the same time, it must be remembered that tizanidine (Sirdalud) cannot be combined with fluvoxamine, an antidepressant from the SSRI group. Simultaneous administration of tizanidine (Sirdalud) and fluvoxamine can lead to a significant decrease in blood pressure and cause complications from the central nervous system.
Thus, due to high efficiency and minor side effects, a number of domestic and foreign experts consider tizanidine (Sirdalud) as the drug of choice for the treatment of acute and subacute myofascial pain in monotherapy and as the drug of first choice for the treatment of chronic myofascial syndrome in combination with other drugs [2 ,13].
Tizanidin (Sirdalud)
in neurological practice
Disturbances in muscle tone, associated pain syndromes, restrictions on motor functions, secondary changes in joints and muscles are part of the clinical manifestations of many diseases of the nervous system. As a rule, the problem of increasing muscle tone – hypertonicity or spasticity – acquires clinical significance [8]. However, the causes of hypertonicity and the mechanisms underlying it may be different, and therefore the treatment of spasticity requires differentiated approaches to treatment.
The use of tizanidine (Sirdalud) is most widely used in the treatment of spasticity in traumatic injuries of the brain and spinal cord, multiple sclerosis, and stroke. With spasticity associated with dystonic disorders, parkinsonism, it is more appropriate to use other drugs (for example, clonazepam, diazepam).
Spasticity leads to significant functional disorders and impaired quality of life of the patient. However, it should be remembered that spasticity itself does not always require treatment. For example, in some patients with severe paresis, the presence of spasticity in the muscles that anatomically oppose gravity (anti-gravity muscles) can make standing and walking easier. In addition, the presence of increased muscle tone can prevent the development of muscle atrophy, soft tissue edema and osteoporosis, as well as reduce the risk of thrombosis of the lower extremities. Indications for the treatment of spasticity are only those cases when, due to increased tone, the “functioning, positioning or comfort” of the patient is disturbed.
The use of tizanidine (Sirdalud) in stroke. In stroke, the main objectives of treatment are not only to reduce the severity of spasticity, but also to improve the functionality of paretic limbs, reduce pain and discomfort associated with high muscle tone, and facilitate care for a paralyzed patient.
The most effective means in the fight against spasticity are exercise therapy and physiotherapy, especially at an early stage. In cases where patients with post-stroke limb paresis have local spasticity, local administration of botulinum toxin preparations can be used. A significant contribution to the treatment of spasticity can be made by the use of anti-spastic drugs (muscle relaxants) for oral administration. The use of muscle relaxants can reduce muscle tone, improve motor functions, facilitate care for an immobilized patient, relieve painful muscle spasms, enhance the effect of physiotherapy and, as a result, prevent the development of contractures. In our country, tizanidine, baclofen, tolperisone, diazepam are used to treat post-stroke spasticity.
An analysis of 20 studies comparing the use of various antispastic agents in a variety of neurological diseases accompanied by spasticity showed that tizanidine, baclofen and diazepam are approximately equally able to reduce spasticity, but tizanidine (Sirdalud) is more effective than other antispastic agents in reducing clonus [14] . Unlike baclofen, tizanidin (Sirdalud) does not cause a decrease in muscle strength with a decrease in spasticity (which is very important for improving the functionality of the limb), it is better tolerated by patients than baclofen and diazepam (when using it, patients are less likely to stop treatment due to side effects) [14,15,20]. Among the side effects identified during the study of tizanidine in patients with post-stroke spasticity, conducted by Gelber (2001), the most common side effects were drowsiness, weakness, dizziness, dry mouth, orthostatic hypotension. These phenomena took place with the abolition or reduction of the dose of the drug. At the same time, no serious side effects were noted during treatment with tizanidine [Gelber, 2001], which allowed the authors to conclude that it is highly safe.
Authors who have conducted studies on the clinical effects of tizanidine (Sirdalud) and many clinicians agree that among muscle relaxants, tizanidine (Sirdalud) is the drug of first choice for the treatment of post-stroke spasticity [7,12,14,15,20].
For the treatment of spasticity due to neurological diseases, higher doses of tizanidine (Sirdalud) are usually used than for the treatment of pain syndromes. Usually the optimal therapeutic effect is achieved with a daily dose of 12 to 24 mg (effective dose range is 2-36 mg). However, given the dose-dependent increase in the risk of side effects with increasing doses of the drug, treatment should be started with small (2-6 mg / day) doses, then gradually increase the dose until a therapeutic effect is achieved, observing individual tolerability (usually 2-6 mg / day). 4 mg every 3–7 days divided into 3 doses per day). If side effects occur, you can temporarily stop increasing the dose (if you do not increase the dose, in many cases the side effects disappear after a few days) and continue increasing the dose after the patient gets used to the drug. This allows, firstly, to select the most effective minimum dose of the drug for a particular patient (in some patients (due to individual variability), a sufficient therapeutic effect may occur when taking smaller doses than recommended standards), as well as to relieve unnecessary suffering of patients with individual poor tolerance to tizanidine (in patients with poor tolerance to tizanidine, side effects appear already at a dose of 2-4 mg / day). Dose titration usually takes 2-4 weeks. The duration of treatment is set individually (from several weeks to several months) [8].
The use of prolonged forms of tizanidine (Sirdalud MR). For long-term use, a dosage form of tizanidine in the form of modified-release capsules (Sirdalud MR), which is available in a dose of 6 mg, is convenient. Clinical experience shows that for most patients the optimal dose is 12 mg / day. (2 capsules), in rare cases, it may be necessary to increase the daily dose to 24 mg. Treatment also begins with a minimum dose of 6 mg (1 capsule), if necessary, gradually increasing the dose by 6 mg (1 capsule) at intervals of 3-7 days.
The use of tizanidine (Sirdalud) in traumatic brain injury. Among muscle relaxants, tizanidine (Sirdalud) is the most commonly used drug for the treatment of spasticity associated with traumatic brain injury [5]. The reasons for prescribing, dose selection tactics and warnings are the same as in the treatment of post-stroke spasticity.
The use of tizanidine (Sirdalud) in multiple sclerosis and spinal injury. Restriction of mobility in patients with multiple sclerosis is associated with a significant increase in spastic muscle tone, mainly in the lower extremities. The basis of the treatment of muscle tone disorders are special exercises that should be performed under the supervision of a specialist in physical therapy. Drug therapy plays a complementary role. Among the drugs used to treat spasticity are tolperisone, baclofen, tizanidine, diazepam. Drug treatment of spastic tone should be individual, controlled by the doctor and the patient himself. This is because most anti-tonus drugs increase the weakness of the paralyzed limbs and may worsen the patient’s condition. In this regard, the dose of the antispastic drug should be gradually increased from the minimum to the optimum, when spasticity decreases, but there is no increase in weakness. Sirdalud in this regard is more preferable than baclofen and diazepam (when using tizanidine (Sirdalud), muscle weakness develops less often; due to excessive relaxation of the sphincters of the bladder when using baclofen, patients often complain of an increase in pelvic disorders; the use of diazepam is associated with a greater frequency development of side effects, drug dependence) [3,17]. Sirdalud is more effective than other muscle relaxants against clonuses [14].
The optimal daily dose of Sirdalud for the treatment of spasticity in multiple sclerosis is 6–8 mg (maximum daily dose is 36 mg). It is also necessary to start treatment with the minimum dose, the step of increasing the dose is 2 mg [3].
In patients with spasticity due to spinal injury, tizanidine (Sirdalud) and baclofen are most commonly used, and diazepam is used to relieve painful muscle spasms. Treatment begins with a minimum dose (4-6 mg Sirdalud), which is gradually brought to a therapeutic dose over several days or weeks, trying to avoid unwanted side effects (muscle weakness and sedation). Baclofen is effective mainly when administered intrathecally; when administered orally, tizanidine (Sirdalud) gives a more pronounced positive effect and is better tolerated by patients than baclofen [18].
For other types of spasticity encountered in neurological practice (with parkinsonism, torsion dystonia, torticollis, ALS), the use of tizanidine (Sirdalud) is not justified. In these cases, the use of clonazepam and diazepam is more appropriate. These drugs have a higher likelihood of side effects, but their antispasmodic effect is more pronounced in these disorders.
Treatment Optimization
when using tizanidine
(Sirdaluda)
A sufficiently wide range of effective doses of tizanidine (Sirdalud) (from 2 to 36 mg / day) allows the use of the drug for short and long courses of treatment of pain syndromes and spasticity as monotherapy or in combination with other drugs. To improve clinical performance, the following recommendations for the practical use of tizanidine (Sirdalud) may be helpful.
Start treatment with small doses of the drug. The development of side effects with the use of tizanidine (Sirdalud) is dose-dependent (for example, the likelihood of side effects with a dose of 12-24 mg is 2 times higher than with a dose of 6-12 mg). At the same time, a sufficient therapeutic effect can sometimes be achieved at lower doses than recommended in the treatment standards. In this regard, it is recommended to start treatment with a minimum dose (2-4 mg), then gradually increase it, observing individual tolerance.
Gradual withdrawal of the drug. After prolonged use of tizanidine (Sirdalud), especially in large doses, it is necessary to gradually discontinue the drug, because. abrupt withdrawal can cause the development of muscle weakness (this is also characteristic of other muscle relaxants).
The use of tizanidin (Sirdalud) to normalize sleep
Side effects of tizanidine (Sirdalud) include increased drowsiness. Therefore, patients who experience drowsiness while taking tizanidine (Sirdalud) should avoid all activities that require increased concentration and responsiveness. At the same time, many patients, especially those with chronic pain syndromes, have disturbed sleep. This side effect of tizanidine (Sirdalud) can be used therapeutically by prescribing the drug at night to improve the patient’s sleep. Given that the effect of tizanidine (Sirdalud) is short-lived, some doctors, in order to maintain the patient’s social activity, prescribe the drug only at night or distribute the main daily dose of the drug in the afternoon and at night. This allows the patient to maintain social activity in the morning (work, drive a car), and in the evening helps to fall asleep, as well as “sleep” other side effects.
Use of tizanidine (Sirdalud) as an antihypertensive
funds
One of the side effects when using tizanidine (Sirdalud) is a moderate decrease in blood pressure. Simultaneous use with antihypertensive agents may enhance the antihypertensive effect. If long-term use of tizanidine (Sirdalud) is necessary (for example, in the treatment of post-stroke spasticity), the hypotensive effect of tizanidine (Sirdalud) can be used to reduce the dose or stop taking blood pressure-lowering drugs if the patient is receiving antihypertensive therapy.
Conclusion
Tizanidine is an effective drug both in the treatment of spasticity in a number of neurological disorders, and for the treatment of a wide range of pain syndromes associated with increased muscle tone. However, the success of the treatment in each particular case depends not only on the correct choice of a particular drug in terms of the symptoms described in the instructions for use and evidence-based studies on the effectiveness of the drug, but also on how the attending physician manages to correlate the features of pharmacokinetic properties of the drug with individual clinical manifestations of the disease in this (specific) patient.

Literature
1. Badokin V.V. The use of Sirdalud in rheumatological practice // Rus. honey. magazine. – 2005. – T. 13, No. 24. – S. 1588-1589.
2. Vorobieva O.V. Possibilities of alpha2-adrenergic agonists in the treatment of myofascial pain // Rus. honey. magazine – 2007. – No. 5. – C. 445–448.
3. Gusev E.I., Boyko A.N. Multiple sclerosis: from new knowledge to new methods of treatment // Ros. honey. magazine. – 2001. – No. 1. – P. 4–10.
4. Danilov A.B. Possibilities of using tizanidine (Sirdalud) in clinical practice. Literature review // RMJ. – 2010. – No. 1. – P. 4–10.
5. Parfenov V.A. Management of patients with spasticity // Rus. honey. magazine. – 2004. – T. 12, No. 10.
6. Parfenov V.A. Diagnosis and treatment of acute pain in the lower back // Rus. honey. magazine – 2007. – T 15 No. 6.
7. Parfenov V.A. Post-stroke spasticity and its treatment // Rus. honey. magazine – 2006. – T. 14, No. 9.
8. Shirokov, E.A. Sirdalud: areas of clinical application // Rus. honey. magazine – 2004. – No. 14. – C. 874–875.
9. Berry H., Hutchinson D.R. Tizanidine and ibuprofen in acute low-back pain: Results of a double-blind multicentre study in general practice // J. Intern. Med. Res. 1988.Vol.16. R. 83–91.
10. Bettucci D., Testa L., Calzoni S. et al. Combination of tizanidine and amitriptyline in the prophylaxis of chronic tension — type headache: evaluation of efficacy and impact on quality of life // J Headache Pain. 2006 Vol. 7(1). P. 34–36.
11. Coward D.M. Tizanidine: Neuropharmacology and mechanism of action // Neurol. 1994 Vol. 44 (Suppl. 9). P. 6–11.
12. Gelber D.A., Good D.C., Dromerick A. et al. Open–Label Dose–Titration Safety and Efficacy Study of Tizanidine Hydrochloride in the Treatment of Spasticity Associated With Chronic Stroke // Stroke. 2001. Vol.32. P. 1841–1846.
13. Hutchinson D.R., Daniels F. A multinational study in general practice to evaluate the effectiveness and tolerability of tizanidine in the treatment of painful muscle spasms // Br. J.Clin. Res. 1990 Vol. 1. P. 39–48.
14. Lataste X., Emre M., Davis C., Groves L. Comparative profile of tizanidine in the management of spasticity // Neurol. 1994 Vol. 44 (suppl 9). P.53–59.
15. Leiphart J.W., Dills C.V., Levy R.M. Alpha2 – adrenergic receptor subtype specificity of intrathecally administered tizanidine used for analgesia for neuropathic pain // J. Neurosurg. 2004 Vol. 101(24). P. 641–647.
16. Sirdalud Ternilin Asia–Pacific Study group. Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasm // Curr. Ther. Res. 1998 Vol. 59. P. 13–22.
17. Smolenski C., Muff S., Smolenski–Kautz S. A double–blind comparative trial of new muscle relaxant, tizanidine (DS 103–282), and baclofen in the treatment of chronic spasticity in multiple sclerosis // Curr. Med. Res. Opin. 1981 Vol. 7(6). P. 374–383.
18. Tarrico M., Adone R., Pagliacci C., Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Systematic Review // The Cochrane Library, 2000. Issue 4.
19. van Tulder M., Becker A., ​​Bekkering T. Et al. European guidelines for the management of acute nonspecific low back pain in primary care // Eur. Spine J. 2006. Vol. 15. (Suppl. 2). S.169–S.191.
20. Wallace J.D. Summary of combined clinical analysis of controlled clinical trials with tizanidine // Neurol. 1994 Vol. 44 (suppl 9). P60-P69.

404 Not Found

Effective Date: November 12, 2015

These Online Terms of Use govern your access to websites controlled by Veropharm, including its subsidiaries and affiliates (collectively, “Veropharm ”) that link to these Online Terms of Use (collectively, the “Veropharm Websites”). These Online Terms of Use do not apply to Veropharm’s websites that do not link to these Online Terms of Use and third party websites to which Veropharm’s websites may be linked. Your use of the Veropharm websites is subject to these Online Terms of Use and the Veropharm Websites Privacy Policy.

To the extent permitted by applicable law, Veropharm reserves the right to amend these Online Terms of Use to reflect technological advances, legal and regulatory changes, and good business practice. If Veropharm makes changes to these Online Terms of Use, the updated version of the Online Terms of Use will reflect the changes and we will notify you by updating the effective date of the Online Terms of Use above.

By accessing and using the Veropharm websites, you agree that you have read, understood and agreed to be bound by these Online Terms of Use in their current version, which you had the opportunity to read when accessing the company’s websites ” Veropharm. If you do not agree to these Online Terms of Use or are dissatisfied with the operation of the Veropharm websites, your sole and exclusive remedy, to the extent permitted by applicable law, is to stop using this Veropharm website.

Disclaimer

You acknowledge and agree that:

a. While we always strive to present the latest developments related to our products and services and other information about Veropharm on Veropharm’s websites, the information is provided “AS IS” and may contain technical inaccuracies, typographical errors or be out of date. Veropharm reserves the right to add, remove or change information contained on Veropharm’s websites at any time without prior notice.

b. Veropharm makes no representations or warranties of any kind or nature regarding the information or data posted on Veropharm’s websites.

To the extent permitted by applicable law, Veropharm hereby disclaims any and all representations or warranties, expressed or implied, statutory, contractual or otherwise, and in no event shall Veropharm be liable for any damages of any kind or nature, including, without limitation, direct, indirect, special (including loss of profits), consequential or incidental, damages arising out of or in connection with the existence or use of the Veropharm websites, and/or information or information posted on the websites of Veropharm, regardless of whether Veropharm anticipated the possibility of such damage.

c. Veropharm is not responsible for and makes no warranties regarding the accuracy, effectiveness, timeliness or acceptability of any information or information obtained from third parties, including hyperlinks to or from third party websites. Except as expressly provided on Veropharm’s websites, Veropharm does not edit, review, or otherwise control content submitted by third parties on bulletin boards, chat rooms, or other similar forums posted on the company’s websites. Veropharm. In this regard, such information should be considered suspicious and is not confirmed by Veropharm.

Veropharm’s websites may contain forward-looking statements that reflect Veropharm’s expectations of future events and business developments. Forward-looking statements involve risks and uncertainties. Actual developments or results may differ materially from those anticipated and depend on a variety of factors, including (but not limited to) the successful completion of ongoing development programs, the results of current or future clinical studies, ongoing commercial product introduction, regulatory approval of pharmaceuticals, credibility and compliance. the validity of patents, the stability of commercial relationships and general economic conditions. Veropharm intends to update its websites regularly, but does not assume any obligation to update any content on the websites.

Your use of

You understand, acknowledge and agree that:

a. By using the Veropharm websites, you agree not to modify or destroy our electronic information posted on the Veropharm websites or on any of our servers. In addition, you also agree not to attempt to circumvent the security measures of Veropharm’s websites and to comply with all applicable local, state, federal and international laws, rules and regulations.

b. You grant Veropharm the right to use any materials that you upload or otherwise transmit to Veropharm websites in accordance with these Online Terms of Use and the Veropharm Websites Privacy Policy , by any means that Veropharm deems preferable, including, but not limited to, copying, displaying, reproducing or publishing in any format, modifying materials, incorporating into other materials or making works based on these materials.

c. Except as specifically provided and agreed in advance by Veropharm, a confidential relationship between Veropharm and a user of the Veropharm websites will not arise if the user of the Veropharm websites sends any or verbal, written or electronic communication from Veropharm (feedback, questions, comments, suggestions, ideas, etc.).

If any Veropharm website requires or asks for such information, and this information contains personally identifiable information (for example, name, address, telephone number, email address), Veropharm intends to obtain, use and store this information with the consent of the respective user in accordance with the provisions specified in the Policy regarding the processing of personal data on the websites of Veropharm.

Otherwise, such communications and any information provided in their context will be treated as non-confidential and Veropharm shall have the right to reproduce, publish or otherwise use this information for any purpose whatsoever, including, without restrictions, research, development, production, use or sale of products involving the implementation of this information. The person who sent any information to Veropharm is fully responsible for its content, including its reliability, accuracy and the fact that it does not violate anyone’s rights, including property rights.

Product labeling

Veropharm’s local websites contain general information about Veropharm and its products that are officially registered in the respective territory and are in free circulation, promotional materials that strictly comply with local legislation, as well as other scientific information that we consider useful for posting on the relevant website for your personal non-commercial purposes or to enhance your professional level if you are a medical, pharmaceutical or other healthcare professional.

However, please note that the local websites of the respective country may contain links to foreign websites of Veropharm. In such a case, product names, descriptions and labels may be more closely related or created under the laws of a country other than your country of permanent residence. Some products may not be available in all countries or may be available under different brand names, strengths, or indications. Many of the products listed can only be dispensed on the prescription of a local healthcare professional.

Except as otherwise agreed in advance by Veropharm, directors, employees, agents or representatives of Veropharm, its subsidiaries and affiliates, do not participate in the provision of medical consultations, diagnosis, treatment or other medical services that could to create any kind of relationship, such as “doctor-patient”, through the websites of Veropharm. In any case, no information about our products posted on our websites should be considered and understood as direct advice from a specialist or a substitute for such advice from an appropriate specialist (physician).

Please note that Veropharm products have contraindications for use, so before using them, you should carefully read the instructions for their use and seek medical advice.

Under no circumstances should the information posted on the Veropharm websites be used for self-diagnosis of your health and possible diseases.

In accordance with the requirements of the legislation of the Russian Federation, the information located in some sections of the Veropharm websites may be intended exclusively for medical and pharmaceutical workers, as well as other workers in the healthcare system. In this case, access to such sections may be restricted in accordance with the rules specified in the Terms of Use section on prescription drugs and medical devices, the use of which requires special training.

To enter such sections, Veropharm reserves the right to ask you to answer some questions related to medicine or pharmaceuticals and / or provide information by performing additional registration on websites for the purpose of confirming the actual status of a medical, pharmaceutical worker or other healthcare professional at the time of visiting the relevant website.

Intellectual property

The information, documents and related graphics published on the websites of Veropharm (hereinafter referred to as the “Information”) are the exclusive property of Veropharm, with the exception of information provided by a third party associated with Veropharm » contractual relationship. Permission to use the Information is granted on the condition that (1) all copies cite the original source and the above copyright notice; (2) Information will be used for informational non-commercial purposes and only for personal use; (3) The information will not be changed in any way; (4) the graphics displayed on this Veropharm website will not be used in isolation from the accompanying text.

Veropharm is not responsible for content provided by a third party, and you may not use or distribute such materials without the permission of their copyright holders. Except as permitted above, no license or right, express or implied, is granted to anyone under any of Veropharm’s patents, trademarks or other proprietary rights.

Veropharm trademarks, trade names, trade dress or products may not be used on VEROPHARM websites without prior written permission from VEROPHARM.

PRIVACY AND SECURITY

Veropharm is committed to maintaining the confidentiality of your information transmitted through this website. We recognize the importance of privacy for our consumers and visitors to Veropharm’s websites. Our use of personal data is governed by our Policy regarding the processing of personal data on Veropharm’s websites, to which you have confirmed your consent by starting to use Veropharm’s websites.

You hereby acknowledge and agree that when submitting your personal data to the Veropharm websites, although Veropharm has effective security measures in place to prevent unauthorized access or interference, the absolute confidentiality of your personal data provided on the websites of Veropharm cannot be entirely dependent on the measures taken by Veropharm.

In the unlikely event that, despite our efforts, tampering or unauthorized access occurs, Veropharm will not be liable for such tampering or unauthorized access, to the extent permitted by applicable law, or for any direct, indirect, special , incidental or consequential damages (also lost profits) from which the consumer or user will suffer, even if Veropharm was previously warned of the possibility of such damage, Veropharm does not guarantee, expressly or impliedly, that the information, provided by the user is not subject to tampering or unauthorized access, and provides no implied warranties as to merchantability or fitness for a particular purpose.

Each user is solely responsible for maintaining the confidentiality of their password.

Limitations of liability

Veropharm does not assume any liability with respect to materials, information or opinions presented, sent or otherwise found on Veropharm’s websites. You may rely on the accuracy of these materials, information and opinions solely at your own risk. Veropharm shall not be liable for harm and/or damage resulting from the use of Veropharm’s websites or materials presented on them.

Veropharm’s websites, site content, products and services provided on or through Veropharm’s websites are provided on an “as is” and “as available” basis, with all its consequences. In no event shall Veropharm or its suppliers or, as appropriate, their directors, employees or agents (hereinafter referred to as “persons associated with Veropharm” be liable for any damages of any kind arising out of or in connection with your use of, or inability to use, the Veropharm websites. 0003

As well as the materials of the Sites, the services provided on or through the Sites, or on any linked Sites, including any special, indirect, punitive, incidental, punitive or consequential damages, including (but (but not limited to) harm, loss of profit or damage arising from delay, suspension of services, viruses, deletion of files or electronic messages, errors, omissions or other inaccuracies on the Veropharm websites or in the materials of the sites, regardless of whether whether this is due to any omissions on the part of Veropharm and whether Veropharm was warned of the possibility of such damage.

Please note that additional legal notices, disclaimers and other terms and conditions may apply to Veropharm websites.

General Provisions

You hereby agree that these Online Terms of Use and the Privacy Policy on Veropharm’s websites constitute a single, indivisible agreement. You hereby agree that by reviewing these Online Terms of Use and the Policy regarding the processing of personal data on the Veropharm websites. You agree to be bound by them, and you acknowledge that these Terms of Online Use, as well as other terms of operation of the Veropharm Websites, are governed by, among other things, the laws of the State of Illinois and other federal laws of the United States.

The laws of the State of Illinois will govern these Online Terms of Use to the extent that the laws of the State of Illinois do not conflict with the mandatory laws of the Russian Federation, in particular consumer protection laws. In the event that the competent judicial authorities determine that any provision of these Online Terms of Use is invalid or unenforceable, you agree that the remaining provisions of these Online Terms of Use will remain in full force and effect.

In connection with the foregoing, any of your actions aimed at your use of the Veropharm websites through your access or other use of the websites and the information contained therein, you acknowledge that you have read these Terms of Online Use and fully agree with such Online Terms of Use.